This trial is testing a new cancer drug, MRTX849, to see if it is effective in treating patients with advanced lung cancer who have a specific gene mutation.
5 Primary · 13 Secondary · Reporting Duration: 62 months
Active Control
Experimental Treatment
950 Total Participants · 8 Treatment Groups
Primary Treatment: MRTX849 Monotherapy · No Placebo Group · Phase 2 & 3
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: